DGAP-News: Eckert&Ziegler: Highest quarterly profit in Q2 2010
(firmenpresse) - Eckert&Ziegler Strahlen- und Medizintechnik AG / Half Year Results
03.08.2010 07:45
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, August 3, 2010 - Berlin-based Eckert&Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a firm specializing in medical use
of radioactivity, recorded sales of EUR 27.2 million in the second quarter
of 2010 (average per quarter 2009: EUR 25.3 million). Compared to the
second quarter of 2009, net income after tax and minority interests
increased by 44% to EUR 2.6 million. This means that the past quarter
recorded the highest profit in the history of the company. Despite a 38%
increase in the number of shares compared to the previous year's quarter,
the income per share was increased by 4% to EUR 0.50/share.
In the first half of 2010, sales of EUR 52.9 million were achieved, an
increase of EUR 0.5 million or 1% over the same period the previous year.
Over the same period, the net income after tax and minority interests
increased by EUR 1.2 million, or 29%, to EUR 5.1 million. However, since
the number of shares increased by 42%, the earnings per share fell by 8% to
EUR 0.99/share.
Once again, the most successful segment was the Industry segment, which we
have renamed 'Isotope Products' segment. For comparison purposes, in 2010
the following explanations once again add sales and income from the new
Environmental Services segment to the Isotope Products segment, in which
the values were still included in 2009. Revenue increased by 9%, the
unadjusted margin by 25% and the EBIT by 65%. The successful integration of
Nuclitec continues. The synergies will become more obvious once
restructuring expenses no longer apply. Compared to the first half of 2009,
the segment was also able to report another increase in sales in the area
of industrial components.
With sales of EUR 14.8 million and an EBIT of EUR 2.4 million, the Therapy
segment achieved a very good result in the first half of the year. Compared
to halved figures excluding special effects for the previous year, the 2010
figures amount to a 2% sales decrease and an 11% increase in the EBIT. The
reduced minority interests had a significant positive effect after the
takeover bid. In the second quarter of 2009, these still amounted to 59%,
while in the second quarter of 2010, minority shareholders of IBt. S.A.
only accounted for 28% of the revenue after tax.
Compared to the first half of 2009, the Radiopharma segment managed to
increase sales by 3% to EUR 10.0 million while keeping costs almost
constant. In addition, there was extraordinary revenue of several hundred
thousand euros from transfers of shares and borrowing of Eckert&Ziegler
EURO-PET Berlin GmbH. Overall, the EBIT increased from EUR 0.5 million to
EUR 1.1 million.
For the financial year 2010, the target for sales is EUR 105 million. The
Executive Board is keeping its profit forecast at EUR 9.5 million (EUR 1.80
per share).
The Eckert&Ziegler Group, with around 530 employees, is one of the
world's largest providers of isotope technology components for radiotherapy
and nuclear medicine.
If you have any questions, please contact:
Eckert&Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-mail: karolin.riehle(at)ezag.de,
www.ezag.com
03.08.2010 07:45 Ad hoc announcement, Financial News and Press Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Language: English
Company: Eckert&Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle(at)ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service
---------------------------------------------------------------------------
Datum: 03.08.2010 - 07:45 Uhr
Sprache: Deutsch
News-ID 31865
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Eckert&Ziegler: Highest quarterly profit in Q2 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert&Ziegler Strahlen- und Medizintechnik AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
